Sun Pharma’s plans to acquire 100% in its Israeli subsidiary Taro Pharma has hit another roadblock. A second shareholder raging capital management opposed Sun's offer of USD 24.5 per share, terming it grossly inadequate, reports CNBC-TV18, Archana Shukla.
first published: Nov 4, 2011 07:29 pm
A collection of the most-viewed Moneycontrol videos.

Live: Can Nifty continue to step up its move to fresh peaks? | Opening Bell

Live: Sensex, Nifty retreat after mounting on new lifetime highs | Closing Bell

Live: Will bulls take Nifty to fresh lifetime highs today? | Opening Bell

Live: Nifty sees best single day rally since June 2025, nears record high | Closing Bell
You are already a Moneycontrol Pro user.

